Jake, in your research, what Biomarker do you think has
Jake, in your research, what Biomarker do you think has been insufficient at least in means of capture, documentation, legitimacy, recording, etc that may have discounted LL's safety profile?
Which surrogate biomarker do you think might be considered that the new HIV trial protocol for safety may collect according to PharmacoVigilance GCP FDA Guidelines and Standards?
Do you think that a possible reason for why Safety or Risk/Benefit Analysis has not been accepted yet is due to the change in Primary End Point where originally is was Viral Load and then for cost purposes, some of the End Points were measured using Receptor Occupancy?
If that is the case, neither of those end points have anything to do with Safety. They only have to do with efficacy.
1
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Office Properties Income Trust Completes Debt Restructuring Today marks an important milestone for Office Properties Income Trust (NASDAQ: OPI). This national real estate investment trust, known for its focus on high-quality office properties, has recently completed a private exchange regarding its previously outlined 4.50% senior unsecured notes due 2025. This...
Continue Reading
Federal Reserve Vice Chair Barr Looks Into Legal Options In an intriguing twist in the political landscape, Federal Reserve Vice Chair for Supervision Michael Barr is reportedly assessing his legal options. This situation comes in light of possible moves from the incoming presidential administration to dispose of him from his position. This potential conflict has left...
Continue Reading
Understanding the Growth of Your Investment in XPO Over Time XPO (NYSE:XPO) has shown remarkable performance in the market over the last decade, outpacing average market returns. With an annualized return rate of 28.88%, XPO has achieved an impressive 16.34% better performance than the market average. Presently, the company's market capitalization stands at approximately...
Continue Reading
Certificate Hero and Brown & Brown Join Forces Certificate Hero recently announced a strategic partnership with Brown & Brown, a prominent leader in the insurance brokerage sector. This collaboration aims to transform the certificate of insurance (COI) issuance process by utilizing Certificate Hero’s state-of-the-art technology. Innovative Solutions for Certificate...
Continue Reading
ConocoPhillips Achieves Remarkable Third Quarter Performance Recently, ConocoPhillips has captivated investors with its impressive third-quarter results, leading to a notable adjustment in the stock's price target. The latest evaluation, conducted by Susquehanna, has raised the target for ConocoPhillips (NYSE: COP) to $148, an increase from the previous $144. This...
Continue Reading
